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ABSTRACT
Objective: To evaluate the application of a chronic disease model (CDM)
for prostate cancer to visual analog scale (VAS) and time trade-off (TTO)
decision tools.
Methods: A total of 138 men (mean age 58 years) viewed a CDM module
for prostate cancer with and without prostate speciﬁc antigen (PSA)
screening. Participants rated their hypothetical quality of life with poten-
tial prostate cancer treatment complications using a CDM-based VAS
decision tool. They were then asked to estimate how many years they
would be willing to trade to be free of treatment complications using a
CDM-based TTO decision tool. The consistency between VAS and TTO
scores and the relationship between scores and preferences for PSA screen-
ing test and hypothetical treatment choice for prostate cancer were then
evaluated.
Results: There was a signiﬁcant relationship between the VAS and TTO
ratings (regression P < 0.001). The TTO tool was sensitive to age. Mean
scores with standard deviations for those less than 58 years compared to
those 58 years and more were 7.78 (1.75) and 8.41 (1.52), respectively
(P = 0.04). Using the VAS tool, men who chose PSA screening had higher
quality of life ratings compared to men who did not choose PSA screening:
7.73 (1.78) and 6.59 (2.39), respectively (P = 0.01). Similar results were
found with the TTO decision tool: 8.33 (1.45) and 7.04 (2.00), respec-
tively (P = 0.005). Men who would hypothetically prefer treatment for
moderately differentiated prostate cancer also had higher TTO scores
compared to men who preferred watchful waiting: 8.54 (1.39) and 7.85
(1.73), respectively (P = 0.04).
Conclusion: CDM-based for prostate cancer, VAS and TTO ratings were
consistent and were concordant with patient preferences for screening;
TTO ratings were also concordant with treatment choice. The use of the
CDM-based TTO ratings to adjust for quality of life in decision analytic
modeling needs to be explored.
Keywords: decision aids, patient preferences, prostate cancer, prostate
cancer screening, utility weights.
Introduction
Many medical problems present the physician and patient with
multiple therapeutic options and no clear best choice. Patient’s
values and preferences are important in the decision-making
process because they can vary considerably. Decision aids are
intended to facilitate decisions that reﬂect a high level of disease-
speciﬁc knowledge, and that reﬂect the patient’s values and
preferences [1–4].
For example, visual analog scale (VAS) ratings and utility
weights are often used to measure patient preference. Utility
weights are also quantitative preference measures used to adjust
for quality of life in decision analytic modeling. The elicitation of
a utility weight, however, is not straightforward because it
involves a trade-off, either in life-years [time trade-off (TTO)] or
risk of death (standard gamble). Moreover, these ratings are done
for a single health state and are assumed to be independent of a
disease or prognosis. As a result, these exercises are often per-
ceived as contrived and only abstractly related to actual choices.
These exercises are also cognitively burdensome, and recent
research has raised concerns about the consistency between
utility elicitation methods [5]. Because of these issues, we have
developed a new method based on a chronic disease model
(CDM) to visually display how quality of life changes over a life
course. Alternative life courses can be depicted to illustrate the
impact of different choices on quality of life.
In this initial study, we applied this approach to prostate
speciﬁc antigen (PSA) screening decisions. After viewing CDM
disease trajectories with and without PSA screening, men then
rated their perceived quality of life with potential treatment
complications resulting from either surgery or radiation for
moderately differentiated prostate cancer, the most common
form of prostate cancer diagnosed after PSA screening, using a
CDM-based VAS decision tool [6]. They were then asked how
many years they were willing to trade, in 0.5-year increments, to
be free of treatment complications using a CDM-based TTO
decision tool. The TTO also used a time line to visually illustrate
the trade-off patients have to make in the event of receiving a
diagnosis of moderately differentiated prostate cancer: a rela-
tively normal life course with a small risk of an earlier death from
prostate cancer versus a longer life course with potential lifelong
prostate cancer treatment complications [6–8].
The purpose of this study was to evaluate whether VAS and
TTO decision tools based on a CDM for prostate cancer could
facilitate quality decision-making. First, we compared ratings
between VAS and TTO methods, and explored the relationship
between VAS and TTO ratings and baseline demographics such
as age and marital status. We then determined whether these
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tools could result in quality decision-making based on prostate
cancer knowledge, as well as consistency with patient preferences
for PSA screening and treatment (surgery or radiation), if they
were to hypothetically have diagnosis of prostate cancer.
Methods
Study Design and Overview
This study was part of a randomized trial comparing Internet-
based decision aids for PSA screening, details of which are pre-
sented elsewhere [9]. Brieﬂy, men aged 50 years or older who
were scheduled for a screening medical exam were invited to
participate. Volunteers were randomly assigned to one of four
intervention arms: 1) a traditional decision aid; 2) CDM for
prostate cancer (the CDM intervention included VAS and TTO
exercises); 3) a combination arm that included an abbreviated
traditional decision aid and CDM, presented in random order;
and 4) a control arm that asked participants to view prostate
cancer Web sites. In this study, we focused on participants who
completed VAS and TTO ratings from the CDM and combina-
tion arms. Nevertheless, because the traditional decision aid
could inﬂuence VAS and TTO ratings in the combination arm,
only participants who completed the CDM ﬁrst are included
here; only 4 of 77 of these participants continued on to view the
traditional decision aid and thus, most of these men were not
likely to have been inﬂuenced by the traditional decision aid.
The introduction to the CDM provided an overview of issues
to consider before PSA screening, followed by animated time lines
or disease trajectories. Participants were then asked to complete
VAS and TTO exercises. Reviewing the complete intervention
required about 30 minutes. Participants then completed a
follow-up questionnaire. This included a validated 10-item pros-
tate cancer knowledge questionnaire [10], as well as questions on
whether they chose PSA testing and whether they would choose
treatment (surgery or radiation) if they were to hypothetically
have diagnosis of moderately differentiated prostate cancer.
Because we were interested in patient preference for PSA testing,
this study focused on self-reported screening choices.
CDM Development
The CDM was animated using IMPACT 4, an XML and Flash-
based software that constructed preference surveys, decision
support tools, and behavioral change tools [11]. Our CDM for
prostate cancer was developed based on a review of the litera-
ture, and included information on prostate cancer, PSA screening
(predictive value, false positives and negatives [12–19], and treat-
ment options for clinically localized prostate cancer (complica-
tions and prognosis with and without active treatment [7,20–
51]). During model development, the content was modiﬁed and
validated based on feedback from a group of health profession-
als, all of whom were nurses or doctors actively involved in the
management of prostate cancer patients. Pilot volunteers then
viewed the CDM and were allowed to make comments and ask
questions as they proceeded through the site. After viewing the
site, they were asked questions regarding the amount of infor-
mation presented, clarity of the information, length of the pre-
sentation, and balance of information. Information from these
pilot tests was used to reﬁne the CDM ultimately used in the
study.
Applying the CDM
Before viewing the prostate cancer CDM, the intervention intro-
duced users to the concept of a disease trajectory by using a
general example to visually illustrate how quality of life can
change over time, ﬁnally ending with death. The trajectory
depicted a life course as a line-graph, with quality of life on the
y-axis and time on the x-axis. Quality of life (on the y-axis) was
anchored between excellent or best health and death, as
described in the training exercises and life course descriptions.
The action-ﬂow added elements to the display as the accompa-
nying narrative soundtrack described likely events from the ages
of 55 to 75 years (the approximate median age of death for
American men) for two hypothetical life courses.
The ﬁrst trajectory described a life course for someone with
moderately differentiated prostate cancer who eventually died
without having had PSA screening or a diagnosis of prostate
cancer; death was most likely from coronary disease. This sce-
nario, however, also included the small possibility of a shorter life
course as a result of dying from prostate cancer [21,52]. The
other trajectory described someone who was screened, received
diagnosis of, and actively treated for prostate cancer. This life
course also included the risks for and descriptions of potential
treatment-related complications [20,22]. Death was assumed to
be from other causes (most likely coronary disease) and not from
prostate cancer.
CDM-Based VAS and TTO Decision Tools
After viewing the prostate cancer CDM with and without PSA
screening, participants then completed CDM-based VAS and
TTO decision tools. Before completing the VAS and TTO deci-
sion tools, participants were given practice examples for both
tools using “wearing glasses” and “blindness” as hypothetical
health states. They were then asked how they would rate their
overall quality of life with potential long-term prostate cancer
treatment complications using a VAS decision tool. The VAS was
anchored between 0 (death) and 100 (excellent or best health),
and increased in 10-unit increments. The VAS score was divided
by 10, resulting in a score with a range similar range to the TTO
score (0 to 10), for analyses.
This was followed by a TTO decision tool that asked partici-
pants how many years they would be willing to trade to be free of
prostate cancer treatment symptoms. The TTO tool used a visual
display similar to the CDM. As noted above, the y-axis repre-
sented quality of life anchored between excellent (or best) health
and death. The time line illustrated how changes in health affect
quality of life, relative to baseline health. The TTO tool was based
on a 10-year trajectory and measured how many years partici-
pants would be willing to trade, in 0.5-year increments, to be free
of prostate cancer treatment-related side effects (Fig. 1).
Participants were ﬁrst asked whether they would prefer a full
10-year life course with potential treatment complications or a
shortened life course (9.5 years) without treatment complica-
tions. If they chose a full life course, this was interpreted to mean
that they were not willing to trade any signiﬁcant time to be free
of treatment-related side effects; if they chose the shortened life
course without treatment complications, they were willing to
trade at least 0.5 year to be free of treatment-related side effects.
The shorter life course without treatment complications was then
decreased by 0.5 year increments until the participant was not
willing to trade any more time to be free of complications. For
example, if they preferred 8.5 years (but not 8.0 years) without
treatment complications, 10 years with treatment complications
would be equivalent to around 8.25 years (the midpoint between
8.0 and 8.5) without treatment complications.
Analyses
Baseline demographics were compared between the two groups
that completed the CDM. The VAS and TTO scores were then
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reviewed to identify discordant (illogical) ratings and to calculate
failure rates for the VAS and TTO tools. Scores that were low on
one scale (less than 3) but high on the other (more than 7) were
considered discordant; because it was not clear whether the
participant understood the exercises, these were not analyzed
further. Failure for a scale was deﬁned as scoring low on that
scale but high on the other (as deﬁned above). Typical logic
checks, for example, expected ranking of scores for one versus
two symptoms, were not included in this study because only one
hypothetical life trajectory was measured. Also, because there
was only one life course and a ﬁxed order of presentation of VAS
followed by TTO, procedural invariance was not measured.
After removal of discordant scores, the relationship between
VAS and TTO scores was explored using least-squared regres-
sion; similarly, the relationship between scores and baseline
demographics was then explored. Prostate cancer knowledge
scores were also determined; these results are only brieﬂy
described in this article as they have been previously detailed [9].
Differences in mean VAS and TTO scores by PSA screening
choice, and hypothetical treatment choices were ﬁrst explored
using analysis of variance (ANOVA). Adjustment for age and
other demographic factors were then explored using logistic
regression. All analyses were done using STATA 9.2. (Stata Corp
LP, College Station, TX)
Results
Demographics and Questionnaire
Two-hundred thirty men were assigned to view the CDM deci-
sion tool, 153 were from the CDM only intervention and 77
from the combination intervention (only those who completed
the CDM ﬁrst are included here, as noted above). Of these, 133
(58%) completed the VAS and TTO exercise. The mean age was
comparable between the two groups: 58 (+/- standard deviation
6) and 59 (5) years, respectively (Table 1). The majority of men
were married (or living as married), college graduates, and white
(Table 1). Among those who answered the postintervention ques-
tionnaire, the majority chose PSA screening in both groups (83%
and 85%, respectively; Table 1). A minority of participants,
however, would hypothetically choose treatment (surgery or
radiation) over watchful waiting if they were to receive diagnosis
of moderately differentiated prostate cancer (29% and 21%;
Table 1).
Figure 1 Time trade-off (TTO) decision tool.The TTO tool animated a hypothetical life course with and without prostate cancer treatment. Based on a 10-year
trajectory, participants were asked how many years they would be willing to trade, in 0.5-year increments, to be free of prostate cancer treatment related side effects.
For example, if they would prefer 8.5 but not 8.0 years without treatment complications, 10 years with treatment complications would be equivalent to around 8.25
years without treatment complications.
Table 1 Baseline demographics and preliminary outcomes by random-
ization group
CDM only
(n = 153)
Combination,
completed CDM
ﬁrst (n = 77)
Age (+/- SD) 58 (+/-6) 59 (+/-5)
Married or living as married (%) 117 (76) 58 (75)
College graduate (%) 107 (70) 56 (72)
White (%) 127 (83) 69 (89)
Chose to have PSA screening (%)* 104 (83) 56 (85)
Would choose treatment (surgery
or radiation) if received
diagnosis of moderately
differentiated prostate
cancer (%)*
35 (29) 30 (21)
Mean VAS Score (+/- SD)† 7.6 (+/-2.0) 7.3 (+/-2.3)
Mean TTO Score (+/- SD)† 7.8 (+/-2.3) 7.8 (+/-1.6)
Knowledge Score (+/- SD)‡ 7.96 (+/-2.03) 7.95 (+/-2.30)
*Among those who answered question.
†Among those who completed VAS or TTO exercise.
‡Knowledge score in the Internet only group was 7.49 (2.34); P = 0.03 CDM groups com-
bined compared to Internet group.
CDM, chronic disease model; SD, standard deviation; VAS, visual analog scale; TTO, time
trade-off.
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CDM-Based VAS and TTO Scores and Prostate
Cancer Knowledge
The mean VAS scores were similar between the two groups: 7.6
(2.0) and 7.3 (2.3), CDM only and combination, respectively.
Mean TTO scores were also similar: 8.2 (1.7) and 7.8 (1.6)
(Table 1). Both groups had comparable prostate cancer knowl-
edge scores; as detailed elsewhere [9], knowledge scores for these
groups were higher than the scores for participants ran-
domized to view public Internet Web sites focused on PSA screen-
ing (signiﬁcantly higher with CDM groups combined, P = 0.03).
Because there were no signiﬁcant baseline differences, the two
groups were then merged.
CDM-Based VAS and TTO: Discordant Results, Failure
Rates and Consistency
Only 2 of the 133 participants with low VAS scores (2.0 and 2.0)
had discordant (illogical) TTO scores (8 and 9.5), an approxi-
mate 2% failure rate for the VAS tool. Five participants had low
TTO scores (0 to 3) with high VAS scores (8.4 to 10.0), an
approximate 5% failure rate. With the exclusion of these 7
outliers (an overall 5% failure rate), 126 participants were avail-
able for further VAS and TTO analyses. There was a signiﬁcant
relationship between VAS and TTO scores (R = 0.2, P < 0.001;
Fig. 2). Adjustment for age, marital status, education, and
ethnicity did not signiﬁcantly alter this relationship.
CDM-Based VAS and TTO: Baseline Demographics
TTO scores, but not VAS scores, were related to age; men under
the median age of 58 years had a perceived lower quality of life
(were willing to trade more years to live without prostate cancer
treatment complications) than those 58 years and over: 7.78
(1.75) versus 8.41 (1.52), P = 0.04 (results not shown). Adjust-
ments using least-squared regression for marital status, education
and ethnicity were not signiﬁcant.
CDM VAS and TTO: PSA Screening Choice
The relationship between mean VAS scores and the decision to
choose PSA screening was also signiﬁcant. Men who chose PSA
screening perceived a higher quality of life with potential prostate
cancer treatment complications in comparison to those who did
not choose PSA screening. Mean VAS scores among those who
did and did not choose PSA screening were 7.73 (1.78) and 6.59
(2.39), respectively (ANOVA, P = 0.01; left portion of Fig. 3).
The relationship between TTO scores and the decision to have
PSA testing was even more signiﬁcant: 8.33 (1.45) and 7.04
(2.00), respectively (P = 0.005; right portion of Fig. 3). Adjust-
ments for age, marital status, education, and ethnicity using
least-squared regression were not signiﬁcant.
CDM VAS and TTO: Hypothetical Treatment Choice
Men who hypothetically chose treatment for moderately differ-
entiated prostate cancer also rated their quality of life with
treatment complications higher than those who chose watchful
waiting. Differences between mean scores, however, were signiﬁ-
cant for TTO only: 8.54 (1.39) and 7.85 (1.73), (P = 0.04;
Fig. 4). Adjustment for age (less than 58 years or 58 years and
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Figure 2 Fitted chronic disease model (CDM) based time trade-off (TTO) and
visual analog scale (VAS) ratings. Using least-squared regression, there was a
signiﬁcant relationship between CDM-based VAS and TTO ratings (R = 0.2,
P < 0.001). CI, conﬁdence interval.
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Figure 3 Chronic disease model visual analog scale (VAS) and time trade-off (TTO) scores by prostate speciﬁc antigen (PSA) screening choice. Ratings with
long-term prostate cancer treatment complications were higher among those who chose PSA screening compared to those who did not chose screening. MeanVAS
scores among those who did and did not choose screening were: 7.73 (1.78) and 6.59 (2.39; P = 0.01). MeanTTO scores were: 8.33 (1.45) and 7.04 (2.00; P = 0.005).
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over) using a logistic regression model was signiﬁcant (P = 0.02
for age coefﬁcient); the interaction between treatment choice and
age was not signiﬁcant.
Discussion
We developed and evaluated a novel CDM for prostate cancer
that animated expected life trajectories resulting from PSA
screening decisions. We then asked participants to rate their
quality of life with potential prostate cancer treatment compli-
cations over an entire life course using a VAS. This was then
followed by a TTO exercise that estimated how many life-years
men would be willing to trade to be free of potential prostate
cancer treatment complications. CDM-based VAS and TTO
scores were consistent (reliable between methods). Participants
also had a good fund of knowledge related to prostate cancer and
PSA screening, and the intervention tools may have helped to
facilitate decisions that were concordant with patient values.
The evaluation of concordance with patient values, however,
was based on an assumption that men with a higher tolerance for
treatment complications would be more likely to choose screen-
ing for early prostate cancer diagnosis and subsequent interven-
tion. On the other hand, men who are less tolerant would be less
likely to want PSA screening for early diagnosis and less willing
to undergo treatment. While the majority of participants chose
PSA screening, screening choice was consistent with VAS and
TTO ratings for treatment complications for moderately differ-
entiated prostate cancer. Based on our study, those who chose
PSA screening had a higher perceived quality with potential
prostate cancer treatment complications compared to those who
did not choose screening using both the VAS and TTO scales.
Between the two methods, TTO scores were more strongly cor-
related to PSA screening preference than VAS scores.
TTO scores were also related to treatment choice. The major-
ity of study participants preferred no intervention (watchful
waiting) over surgery or radiation if they were to hypothetically
have diagnosis of moderately differentiated localized prostate
cancer. This is strikingly different from regional US registries
where only a minority of men (8% to 18.5% for all grades
of localized cancer) choose expectant management [53,54], sug-
gesting that the utilization of radiation or surgery for moderately
differentiated prostate cancer that poses a limited threat to lon-
gevity may be driven by poor quality decisions. The animated
display of contrasting a full life course with treatment complica-
tions or a relatively normal life with small risk of a shortened life
expectancy as a result of death from prostate cancer may have
been an effective way to communicate the actual trade-off in the
event of a diagnosis of localized moderately differentiated pros-
tate cancer. Nevertheless, whether ﬁndings would differ in the
event of an actual diagnosis of prostate cancer and in conjunction
with oncology and radiation consultations needs to be further
explored.
Interestingly, the TTO, but not the VAS decision tool, was
also independently related to age. Younger men were willing to
trade more years to be free of prostate cancer treatment compli-
cations. Younger men may have assumed that they have more
years to live, and may have placed less value additional time than
older men. Younger men would have had to live longer with these
complications and may have perceived the longer life course with
treatment complications as more burdensome than older men.
Older men may have also had experience with prostate related
lower urinary obstructive urinary symptoms and erectile
dysfunction; thus, they may have perceived prostate cancer treat-
ment symptoms as less bothersome compared to men who have
not had experience with these symptoms [22].
Measuring Patient Preference
As this is a novel application of CDM to measure patient pref-
erence, it is difﬁcult to directly compare our results to other
studies. Nevertheless, it is important to note that conventional
VAS and TTO ratings are often inconsistent [55], raising con-
cerns about the use of such scales in clinical practice. Conven-
tional TTO utility exercises are framed under conditions of
certainty and are not presented in the context of a disease or
prognosis. Conventional approaches also measure utility weights
for single-item health states; this is unrealistic for many chronic
medical conditions such as long-term side effects resulting from
prostate cancer treatment [22]. Based on our previous study, we
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Figure 4 Chronic disease model visual analog scale (VAS) and time trade-off (TTO) scores by treatment choice. TTO ratings with long-term prostate cancer
treatment complications were signiﬁcantly higher among those who would hypothetically prefer treatment (surgery or radiation) for moderately differentiated
prostate cancer compared to those who would not prefer treatment. Mean TTO scores were 8.54 (1.39) and 7.85 (1.73; P = 0.04).
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noted that quality of life diminished with increasing number of
complications. Aside from directly measuring utility weights for
combination health states, there was no clear way to derive
utility weights for combination health states based on single-item
utility weights [56].
The use of contrasting life trajectories may have been an
effective way to measure preferences for multi-symptom health
states in the context of a diagnosis and prognosis over many
years. The outcomes were also framed under conditions of uncer-
tainty, a more accurate representation of circumstances under
which patients make most treatment decisions for complicated
medical illnesses. In this sense, our approach is similar to the
healthy life-year equivalent model proposed by Mehrez, Birch
and Gafni [57,58]. The effects of individual health states,
however, cannot be determined with this approach, and changes
in technology (subsequent complication rates etc.) would neces-
sitate a revision of the life course description. Nonetheless, effec-
tive risk communication is extremely important because patients
need to understand the limitations, beneﬁts, and expected out-
comes of medical interventions. In the case of PSA screening,
decision aids must effectively communicate complex information
on the limitations, uncertain beneﬁts, and future consequences of
PSA screening.
Implications for Decision Modeling
Finally, utility weights derived from conventional TTO exercises
are used in decision analytic models to adjust for quality of life.
Traditional models, however, incorporate outcomes for indi-
vidual and combination health states separately, requiring corre-
sponding individual and combination utility weights. Using
prostate cancer treatment outcomes as an example, utilities for
any combination of sexual, bowel, urinary need to be measured
[21,56]. Direct measurement of all these health states is a bur-
densome task, often resulting in unreliable weights [55]. Alter-
natively, a model could hypothetically be built based on expected
life trajectories. By assigning a single weight to a life course, the
decision tree can be pared down to one of several arms with
corresponding adjustment for quality of life. How a simpliﬁed
model compares to a more traditional model remains to be
determined.
Study Limitations
Because this is an exploratory study, there are several important
limitations. Although our study was Internet-based and limited
to those with a cable or digital subscriber line modem, the
software could be developed to run on any computer platform.
Results from the TTO only and combination arms from the
original intervention study were analyzed together because base-
line parameters and initial results were similar between these
groups. Study participants were mainly white, highly educated,
employed, and computer literate. We do not know how accept-
able this method would be to less-educated and more diverse
populations.
Low completion rates for the VAS and TTO exercises also
need to be acknowledged. Although there may be several reasons
(viewer fatigue, cognitive burden, etc.), future studies need to
include prompts to encourage completion of the decision tools.
Because we explored only one life course, logic checks were also
not built into the study. The tools were also placed in a ﬁxed
order, VAS followed to by the TTO, so that participants rated
perceived quality of life using an easier scale before proceeding to
a more complicated TTO scale. This ﬁxed order may have con-
tributed to the good concordance between the two scales; how
the VAS exercise inﬂuenced the TTO results, and whether the
TTO tool could be used on its own, cannot be determined from
this study. Similarly, because all participants viewed the CDM for
prostate cancer and then completed the VAS and TTO decision
tools, we cannot determine whether the CDM alone would result
in similar decisions for PSA screening and hypothetical choices
for prostate cancer treatment.
Therefore, future studies should ideally explore a CDM
module with and without decision tools. Although we explored
actual PSA screening decisions, treatment decisions were hypo-
thetical and future work needs to explore the CDM-based VAS
and TTO decision tools in the event at actual treatment deci-
sions. TTO scores also appear to be age-sensitive but because of
our narrow age range, the psychometric properties with respect
to age could not be fully explored here.
Conclusions
In summary, we have developed a new approach to informed
decision-making by using a CDM and building upon VAS and
TTO methodology. This study provides preliminary evidence
suggesting that VAS and TTO ratings based on a CDM for
prostate cancer in middle-aged and older men are reliable
methods for measuring quality of life (concordant ratings
between methods with overall low failure rates). TTO ratings
may be superior to VAS ratings because they were more sensitive
to PSA screening choice and were also related to hypothetical
treatment choice. This application of CDM methodology is a
promising approach to facilitate high-quality decision-making.
Source of ﬁnancial support: CDC U57/CCU920678-04-1, Department for
Veterans Affairs.
References
1 Sepucha K, Ozanne E, Silvia K, et al. An approach to measuring
the quality of breast cancer decisions. Patient Educ Couns 2007;
65:261–9.
2 Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose
one treatment over another?: a review of patient decision making
for localized prostate cancer. Cancer 2006;106:1865–74.
3 Denberg TD, Melhado TV, Steiner JF. Patient treatment prefer-
ences in localized prostate carcinoma: the inﬂuence of emotion,
misconception, and anecdote. Cancer 2006;107:620–30.
4 Sepucha KR, Fowler FJ Jr, Mulley AG Jr. Policy support for
patient-centered care: the need for measurable improvements in
decision quality. Health Aff (Project Hope) 2004;(Suppl. Web
Exclusives): VAR54–62.
5 Elkin EB, Cowen ME, Cahill D, et al. Preference assessment
method affects decision-analytic recommendations: a prostate
cancer treatment example. Med Decis Making 2004;24:504–
10.
6 Stanford JL Sr, Coyle LM, Cerhan J, et al. Prostate cancer trends
1973–1995. SEER Program, National Cancer Institute, NIH Pub,
1999; No. 99–4543.
7 Han M, Partin AW, Zahurak M, et al. Biochemical (prostate
speciﬁc antigen) recurrence probability following radical pros-
tatectomy for clinically localized prostate cancer. J Urol 2003;
169:517–23.
8 Hall HI, Satariano WA, Thompson T, et al. Initial treatment for
prostate carcinoma in relation to comorbidity and symptoms.
Cancer 2002;95:2308–15.
9 Frosch DL, Bhatnagar V, Tally S, et al. Internet patient decision
support: a randomized controlled trial comparing alternative
approaches for men considering prostate cancer screening. Arch
Intern Med 2008;168:363–9.
106 Bhatnagar et al.
10 Radosevich DM, Partin MR, Nugent S, et al. Measuring patient
knowledge of the risks and beneﬁts of prostate cancer screening.
Patient Educ Couns 2004;54:143–52.
11 Lenert LA, Michelson D, Flowers C, Bergen MR. IMPACT: an
object-oriented graphical environment for construction of multi-
media patient interviewing software. Proceedings/the Annual
Symposium on Computer Application in Medical Care. 1995:
319–23.
12 Harris R, Lohr KN. Screening for Prostate Cancer: an update of
the evidence for the U.S. Preventive Services Task Force. Ann
Intern Med 2002;137:917–29.
13 Bunting PS. Screening for prostate cancer with prostate-speciﬁc
antigen: beware the biases. Clin Chim Acta 2002;315:71–97.
14 Zoorob R, Anderson R, Cefalu C, Sidani M. Cancer screening
guidelines. Am Fam Physician 2001;63:1101–12.
15 Balk SP, Ko YJ, Bubley GJ. Biology of prostate-speciﬁc antigen.
J Clin Oncol 2003;21:383–91.
16 Ransohoff DF, McNaughton Collins M, Fowler J, Floyd J. Why
is prostate cancer screening so common when the evidence is so
uncertain? a system without negative feedback. Am J Med 2002;
113:663–7.
17 Partin AW, Hanks GE, Klein EA, et al. Prostate-speciﬁc antigen
as a marker of disease activity in prostate cancer. Oncology
(Williston Park) 2002;16:1218–24; discussion 1224, 1227–8
passim.
18 Stephenson RA. Prostate cancer trends in the era of prostate-
speciﬁc antigen. An update of incidence, mortality, and clinical
factors from the SEER database. Urol Clin North Am 2002;
29:173–81.
19 Harris R, Lohr KN. Screening for prostate cancer: an update of
the evidence for the U.S. Preventive Services Task Force. Ann
Intern Med 2002;137:917–29.
20 Bhatnagar V, Kaplan RM. Treatment options for prostate cancer:
evaluating the evidence. Am Fam Physician 2005;71:1915–22.
21 Bhatnagar V, Stewart ST, Bonney WW, Kaplan RM. Treatment
options for localized prostate cancer: quality-adjusted life years
and the effects of lead-time. Urology 2004;63:103–9.
22 Bhatnagar V, Stewart ST, Huynh V, et al. Estimating the risk of
long-term erectile, urinary and bowel symptoms resulting from
prostate cancer treatment. Prostate Cancer Prostatic Dis
2006;9:136–46.
23 Albertsen PC. Who needs to be treated? Mol Urol 1999;3:183–
90.
24 Blute ML, Bergstralh EJ, Iocca A, et al. Use of Gleason score,
prostate speciﬁc antigen, seminal vesicle and margin status to
predict biochemical failure after radical prostatectomy. J Urol
2001;165:119–25.
25 Sandler HM, Dunn RL, McLaughlin PW, et al. Overall survival
after prostate-speciﬁc-antigen-detected recurrence following con-
formal radiation therapy. Int J Radiat Oncol Biol Phys 2000;
48:629–33.
26 Horwich A, Parker CC, Huddart RA, Dearnaley DP. Manage-
ment of early prostate cancer. Ann Oncol 2002;13:83–7.
27 Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial
comparing radical prostatectomy with watchful waiting in early
prostate cancer. N Engl J Med 2002;347:781–9.
28 Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatec-
tomy versus watchful waiting in early prostate cancer. N Engl J
Med 2005;352:1977–84.
29 Albertsen PC. Early-stage prostate cancer. When is observation
appropriate? Hematol Oncol Clin North Am 1996;10:611–25.
30 Pound CR, Partin AW, Eisenberger MA, et al. Natural history of
progression after PSA elevation following radical prostatectomy.
JAMA 1999;281:1591–7.
31 Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of
radiation side-effects of conformal and conventional radiotherapy
in prostate cancer: a randomised trial. Lancet 1999;353:267–72.
32 Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the
efﬁcacy of local therapies for localized prostate cancer in the
prostate-speciﬁc antigen era: a large single-institution experience
with radical prostatectomy and external-beam radiotherapy. J
Clin Oncol 2002;20:3376–85.
33 Arai Y. Radical prostatectomy: time trends, morbidity and
quality of life. Int J Urol 2001;8(Suppl.):S15–8.
34 Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after
radical prostatectomy or watchful waiting. N Engl J Med 2002;
347:790–6.
35 Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes
after primary androgen deprivation therapy: results from the
Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750–7.
36 Litwin MS, Melmed GY, Nakazon T. Life after radical prostate-
ctomy: a longitudinal study. J Urol 2001;166:587–92.
37 Fowler FJ Jr, Barry MJ, Lu-Yao G, et al. Outcomes of external-
beam radiation therapy for prostate cancer: a study of Medicare
beneﬁciaries in three surveillance, epidemiology, and end results
areas. J Clin Oncol 1996;14:2258–65.
38 Madalinska JB, Essink-Bot ML, de Koning HJ, et al. Health-
related quality of life in patients with screen-detected versus clini-
cally diagnosed prostate cancer preceding primary treatment.
Prostate 2001;46:87–97.
39 Lim AJ, Brandon AH, Fiedler J, et al. Quality of life: radical
prostatectomy versus radiation therapy for prostate cancer. J Urol
1995;154:1420–5.
40 Hamilton AS, Stanford JL, Gilliland FD, et al. Health outcomes
after external-beam radiation therapy for clinically localized pros-
tate cancer: results from the Prostate Cancer Outcomes Study. J
Clin Oncol 2001;19:2517–26.
41 Storey MR, Pollack A, Zagars G, et al. Complications from radio-
therapy dose escalation in prostate cancer: preliminary results
of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48:635–
42.
42 Fransson P, Damber JE, Tomic R, et al. Quality of life and symp-
toms in a randomized trial of radiotherapy versus deferred treat-
ment of localized prostate carcinoma. Cancer 2001;92:3111–9.
43 Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high
dose three-dimensional conformal radiotherapy in patients with
localized prostate carcinoma. Cancer 1999;85:2460–8.
44 Smith DS, Carvalhal GF, Schneider K, et al. Quality-of-life out-
comes for men with prostate carcinoma detected by screening.
Cancer 2000;88:1454–63.
45 McCammon KA, Kolm P, Main B, Schellhammer PF. Compara-
tive quality-of-life analysis after radical prostatectomy or external
beam radiation for localized prostate cancer. Urology 1999;
54:509–16.
46 Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL.
Quality of life and treatment outcomes: prostate carcinoma
patients’ perspectives after prostatectomy or radiation therapy.
Cancer 1997;79:1977–86.
47 Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual
function after radical prostatectomy for clinically localized
prostate cancer: the Prostate Cancer Outcomes Study. JAMA
2000;283:354–60.
48 Jonler M, Nielsen OS, Wolf H. Urinary symptoms, potency, and
quality of life in patients with localized prostate cancer followed
up with deferred treatment. Urology 1998;52:1055–62; discus-
sion 1063.
49 Althof SE. Quality of life and erectile dysfunction. Urology 2002;
59:803–10.
50 Krane RJ. Urinary incontinence after treatment for localized pros-
tate cancer. Mol Urol 2000;4:279–86; discussion 287.
51 Rabbani F, Stapleton AM, Kattan MW, et al. Factors predicting
recovery of erections after radical prostatectomy. J Urol 2000;
164:1929–34.
52 Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk
analysis of men aged 55 to 74 years at diagnosis managed
conservatively for clinically localized prostate cancer. JAMA
1998;280:975–80.
53 Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment
choices for men with clinically localized prostate carcinoma
detected by screening. Cancer 2000;88:1122–30.
54 Harlan LC, Potosky A, Gilliland FD, et al. Factors associated
with initial therapy for clinically localized prostate cancer:
Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001;93:
1864–71.
Disease Trajectory for Prostate Cancer Decision-Making 107
55 Souchek J, Stacks JR, Brody B, et al. A trial for comparing
methods for eliciting treatment preferences from men with
advanced prostate cancer: results from the initial visit. Med Care
2000;38:1040–50.
56 Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for
prostate cancer health states in men aged 60 and older. Med Care
2005;43:347–55.
57 Gafni A, Birch S, Mehrez A. Economics, health and health
economics: HYEs (healthy-years equivalent) versus QALYs
(quality-adjusted live-year). J Health Econ 1993;12:325–
39.
58 Mehrez A, Gafni A. Healthy-years equivalents versus quality-
adjusted life years: in pursuit of progress. Med Decis Making
1993;13:287–92.
108 Bhatnagar et al.
